levofloxacin; amoxicillin/clavulanate
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Otitis Media
Conditions
Otitis Media
Trial Timeline
Nov 1, 2002 → May 1, 2005
NCT ID
NCT00051753About levofloxacin; amoxicillin/clavulanate
levofloxacin; amoxicillin/clavulanate is a phase 3 stage product being developed by Johnson & Johnson for Otitis Media. The current trial status is completed. This product is registered under clinical trial identifier NCT00051753. Target conditions include Otitis Media.
What happened to similar drugs?
2 of 11 similar drugs in Otitis Media were approved
Approved (2) Terminated (2) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00051753 | Phase 3 | Completed |
Competing Products
15 competing products in Otitis Media
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0% | Yuhan | Phase 1/2 | 24 |
| ofloxacin otic solution 0.3% | Daiichi Sankyo | Phase 3 | 40 |
| levofloxacin | Johnson & Johnson | Phase 3 | 40 |
| V114 | Merck | Phase 3 | 40 |
| Montelukast + Placebo | Merck | Approved | 43 |
| 7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine | Merck | Phase 3 | 40 |
| Prevenar | Pfizer | Pre-clinical | 26 |
| Zmax | Pfizer | Phase 3 | 40 |
| Observational | Pfizer | Pre-clinical | 26 |
| Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine | Pfizer | Approved | 43 |
| amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR | Pfizer | Phase 3 | 40 |
| 60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR | Pfizer | Phase 2 | 35 |
| Telithromycin (HMR3647) | Sanofi | Phase 3 | 40 |
| telithromycin (HMR3647) | Sanofi | Phase 3 | 32 |
| Telithromycin + Azithromycin | Sanofi | Phase 3 | 32 |